Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells

Journal of Drug Targeting

Volumn 21, Issue 3, 2013, Pages 240-249

  Accardo, Antonella ^a,b   Mansi, Rosalba ^c   Salzano, Giuseppina ^a   Morisco, Anna ^d   Aurilio, Michela ^d   Parisi, Antonio ^a   Maione, Francesco ^a   Cicala, Carla ^a   Ziaco, Barbara ^b   Tesauro, Diego ^a,b   Aloj, Luigi ^d   De Rosa, Giuseppe ^a   Morelli, Giancarlo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Invectors srl   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Animal studies; Anticancer efficacy; Bombesin peptide; Doxorubicin delivery; Liposomes for drug delivery

Indexed keywords

AMINO ACID DERIVATIVE; AMPHOPHILE; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; DOXORUBICIN; INDIUM 111; LIPOSOME; LUTETIUM 177; MACROGOL; PENTETIC ACID; PEPTIDE DERIVATIVE; TETRAXETAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; ISOTOPE LABELING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ZETA POTENTIAL;

EID: 84875916349     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.741138     Document Type: Article

References (28)

1. Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR. (2011). Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med, 52, 1970-1978.
2. Accardo A, Tesauro D, Aloj L, Tarallo L, Arra C, Mangiapia G, Vaccaro M, Pedone C, Paduano L, Morelli G. (2008). Peptidecontaining aggregates as selective nanocarriers for therapeutics. ChemMedChem, 3, 594-602.
3. Accardo A, Mansi R, Morisco A, Mangiapia G, Paduano L, Tesauro D, Radulescu A, Aurilio M, Aloj L, Arra C, Morelli G. (2010). Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol Biosyst, 6, 878-887.
4. Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G. (2012). Peptidemodified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent. Int J Nanomedicine, 7, 2007-2017.
5. Battey JF, Way JM, Corjay MH, Shapira H, Kusano K, Harkins R, Wu JM, Slattery T, Mann E, Feldman RI. (1991). Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA, 88, 395-399.
6. Chan KY, Vermeersch S, de Hoon J, Villalón CM, Maassenvandenbrink A. (2011). Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. Pharmacol Ther, 129, 332-351.
7. Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, Upendran A, Kulkarni RR, Kan P, Fent GM, Casteel SW, Smith CJ, Boote E, Robertson JD, Cutler C, Lever JR, Katti KV, Kannan R. (2010). Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci USA, 107, 8760-8765.
8. Chang WC, White PD. (2000). Fmoc solid phase peptide synthesis. Oxford, UK: Oxford Univ Press.
9. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF. (1993). BRS-3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem, 268, 5979-5984.
10. Fleischmann A, Waser B, Reubi JC. (2007). Overexpression of gastrinreleasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol, 29, 421-433.
11. Gugger M, Reubi JC. (1999). Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol, 155, 2067-2076.
12. Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A. (2008). Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem, 19, 1871-1879.
13. Hosta-Rigau L, Olmedo I, Arbiol J, Cruz LJ, Kogan MJ, Albericio F. (2010). Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem, 21, 1070-1078.
14. Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, Sohn MH. (2010). Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res, 27, 712-721.
15. Llinares M, Devin C, Chaloin O, Azay J, Noel-Artis AM, Bernad N, Fehrentz JA, Martinez J. (1999). Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res, 53, 275-283.
16. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR. (2009). Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res, 15, 5240-5249.
17. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR. (2011). Development of a potent DOTAconjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging, 38, 97-107.
18. Markwalder R, Reubi JC. (1999). Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res, 59, 1152-1159.
19. Martin AL, Hickey JL, Ablack AL, Lewis JD, Luyt LG, Gillies ER. (2009). Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanopart Res, 12, 1599-1608.
20. Mendoza-Sánchez AN, Ferro-Flores G, Ocampo-García BE, Morales-Avila E, de M Ramírez F, De León-Rodríguez LM, Santos-Cuevas CL, Medina LA, Rojas-Calderón EL, Camacho-López MA. (2010). Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. J Biomed Nanotechnol, 6, 375-384.
21. Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT, Spindel ER. (1995). Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: Identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA, 92, 6205-6209.
22. Parry JJ, Kelly TS, Andrews R, Rogers BE. (2007). In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem, 18, 1110-1117.
23. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ. (2003). MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem, 14, 756-763.
24. Schmitt L, Dietrich C. (2004). Synthesis and characterization of chelatorlipids for reversible immobilization of engineered proteins at selfassembled lipid interfaces. J Am Chem Soc, 116, 8485-8491.
25. Smith CJ, Volkert WA, Hoffman TJ. (2005). Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol, 32, 733-740.
26. Stewart JC. (1980). Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem, 104, 10-14.
27. Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R, Battery J. (1991). cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron, 6, 421-430.
28. Zhu YF, Chen C. (2004). Recent advances in small molecule gonadotrophin-releasing hormone receptor antagonists. Expert Opin Ther Pat, 14, 187-199.